Topiramate in the Treatment of Binge Eating Disorder Associated With Obesity: A Randomized, Placebo-Controlled Trial

• Published in: The American journal of psychiatry Vol. 160; no. 2; pp. 255 - 261
• Main Authors: McElroy, Susan L., Arnold, Lesley M., Shapira, Nathan A., Keck, Paul E., Rosenthal, Norman R., Karim, M. Rezaul, Kamin, Marc, Hudson, James I.
• Format: Journal Article
• Language: English
• Published: Washington, DC American Psychiatric Publishing 01.02.2003; American Psychiatric Association
• Subjects: Ambulatory Care; Anticonvulsants - administration & dosage; Anticonvulsants - therapeutic use; Binge eating; Biological and medical sciences; Bulimia - drug therapy; Bulimia - epidemiology; Clinical trials; Comorbidity; Double-Blind Method; Drug Administration Schedule; Drug therapy; Eating disorders; Fructose - administration & dosage; Fructose - analogs & derivatives; Fructose - therapeutic use; Humans; Medical sciences; Miscellaneous; Neuropharmacology; Obesity; Obesity - complications; Obesity - epidemiology; Pharmacology. Drug treatments; Placebos; Treatment Outcome; Human; Short term; Obesity; Topiramate; Psychotropic; Toxicity; Treatment efficiency; Nutrition disorder; Weight loss; Eating disorder; Dose activity relation; Symptomatology; Concomitant disease; Chemotherapy; Binge eating; Treatment; Follow up study; Young adult; Adult; Nutritional status
• ISSN: 0002-953X; 1535-7228
• DOI: 10.1176/appi.ajp.160.2.255

OBJECTIVE: Binge eating disorder is associated with obesity. Topiramate is an antiepileptic agent associated with weight loss. The objective of this study was to evaluate topiramate in the treatment of binge eating disorder associated with obesity. METHOD: For this 14-week, double-blind, flexible-dose (25-600 mg day) topiramate trial, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index ≥30 kg m2) were randomly assigned to receive topiramate (N=30) or placebo (N=31). The primary efficacy measure was binge frequency. The primary analysis of efficacy was a repeated-measures random regression with treatment-by-time as the effect measure. RESULTS: Compared with placebo, topiramate was associated with a significantly greater rate of reduction in binge frequency, binge day frequency, body mass index, weight, and scores on the Clinical Global Impression severity scale and the Yale-Brown Obsessive Compulsive Scale (modified for binge eating). Topiramate was also associated with significantly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly higher level of response than placebo. The mean weight loss for topiramate-treated subjects who completed the study was 5.9 kg. Median topiramate dose was 212 mg day (range=50-600). Nine patients (three receiving placebo, six given topiramate) discontinued because of adverse events. The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2). CONCLUSIONS: Topiramate was efficacious and relatively well tolerated in the short-term treatment of binge eating disorder associated with obesity.